Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Sander

Showing results (81-90 of 98) with videos related to

Pageof 10
Sort By:
Plos One|June 17, 2009
Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85AKathryn T Whelan, Ansar A Pathan, Clare R Sander, et al.
Plos One|September 3, 2011
Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85AKristin L Griffiths, Ansar A Pathan, Angela M Minassian, et al.
Vaccine|July 14, 2012
Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adultsAnsar A Pathan, Angela M Minassian, Clare R Sander, et al.
Vaccine|August 7, 2008
Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1Helen A Fletcher, Ansar A Pathan, Tamara K Berthoud, et al.
Plos One|October 25, 2007
Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trialsAnsar A Pathan, Clare R Sander, Helen A Fletcher, et al.
The Journal of Pathology|February 28, 2007
Flightless I deficiency enhances wound repair by increasing cell migration and proliferationA J Cowin, D H Adams, X L Strudwick, et al.
Journal of Medical Microbiology|July 12, 2022
Introducing biomarkers for invasive fungal disease in haemato-oncology patients: a single-centre experienceAnthony W Martinelli, Callum B Wright, Marta S Lopes, et al.
BMC Infectious Diseases|December 4, 2014
Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85ARachel Tanner, Kristina Kakalacheva, Ellen Miller, et al.
American Journal of Respiratory and Critical Care Medicine|January 20, 2009
Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individualsClare R Sander, Ansar A Pathan, Natalie E R Beveridge, et al.
Tuberculosis (Edinburgh, Scotland)|September 20, 2008
A comparison of IFNgamma detection methods used in tuberculosis vaccine trialsNatalie E R Beveridge, Helen A Fletcher, Jane Hughes, et al.
Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
Plos One|June 17, 2009
Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85AKathryn T Whelan, Ansar A Pathan, Clare R Sander, et al.
Plos One|September 3, 2011
Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85AKristin L Griffiths, Ansar A Pathan, Angela M Minassian, et al.
Vaccine|July 14, 2012
Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adultsAnsar A Pathan, Angela M Minassian, Clare R Sander, et al.
Vaccine|August 7, 2008
Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1Helen A Fletcher, Ansar A Pathan, Tamara K Berthoud, et al.
Plos One|October 25, 2007
Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trialsAnsar A Pathan, Clare R Sander, Helen A Fletcher, et al.
The Journal of Pathology|February 28, 2007
Flightless I deficiency enhances wound repair by increasing cell migration and proliferationA J Cowin, D H Adams, X L Strudwick, et al.
Journal of Medical Microbiology|July 12, 2022
Introducing biomarkers for invasive fungal disease in haemato-oncology patients: a single-centre experienceAnthony W Martinelli, Callum B Wright, Marta S Lopes, et al.
BMC Infectious Diseases|December 4, 2014
Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85ARachel Tanner, Kristina Kakalacheva, Ellen Miller, et al.
American Journal of Respiratory and Critical Care Medicine|January 20, 2009
Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individualsClare R Sander, Ansar A Pathan, Natalie E R Beveridge, et al.
Tuberculosis (Edinburgh, Scotland)|September 20, 2008
A comparison of IFNgamma detection methods used in tuberculosis vaccine trialsNatalie E R Beveridge, Helen A Fletcher, Jane Hughes, et al.
Pageof 10